HELP · Cybin Inc.

The thesis

Helus Pharma's shares remain a single clinical bet: the APPROACH Phase 3 trial of HLP003 in major depressive disorder reports in Q4 2026, and a statistically significant gain over placebo on the six-week depression score settles the case. The shares closed at $10.52 on 27 October 2026, 25.0% below the 52-week high of $14.02 and 29.2% above the close three months earlier.

Three things happened after the 15 October 2026 note. Wells Fargo raised its price target to $22 from $16 and kept Overweight on 22 October 2026. The company reaffirmed Q4 2026 topline timing for APPROACH in its 22 October 2026 clinical program update. On 27 October 2026 the company announced that co-founders Eric So and Paul Glavine are leaving their executive roles while keeping board seats, and that director Mark Lawson is now independent Board Chair. None of these changes the clinical timetable or the endpoint that decides the case.

The narrative is maturing: the timetable is well known and was restated on 14 September 2026 and again in October, and the shares have moved within a narrow range since 14 October 2026 (a $10.38 close then, $10.52 on 27 October 2026). The case fails on a missed primary endpoint or a topline that slips past 31 December 2026.

Bullish and bearish views on Cybin Inc.

The bull case on Cybin Inc. (HELP), in brief: Late-stage asset with a defined readout. The bear case: The readout can end the story.

Bull case

• Late-stage asset with a defined readout. HLP003 holds FDA Breakthrough Therapy Designation, and APPROACH enrolled 223 adults ahead of schedule (company announcement, 21 July 2026). Topline will include the six-week primary endpoint, a twelve-week secondary endpoint and safety data (H.C. Wainwright conference, 14 September 2026).
• Timetable reaffirmed twice in October. The company's 22 October 2026 clinical program update and the 27 October 2026 leadership release both state that topline data are still expected in Q4 2026. A second Phase 3 study, EMBRACE, is already enrolling.
• Sell-side targets keep rising. Wells Fargo lifted its target to $22 from $16 on 22 October 2026 (Benjamin Burnett, Overweight). TD Cowen raised its target to $62 from $8 on 20 August 2026. TipRanks showed six analysts on 2 October 2026 with an average target of $35.33 and no Hold or Sell ratings.
• Earlier data showed a large effect. The company's Phase 1/2 data showed a reduction of about 23 points on the Montgomery-Åsberg Depression Rating Scale (MADRS) at 12 months. That sample was small, and a placebo-controlled Phase 3 is the first test at scale.

Bear case

• The readout can end the story. HLP003 is the only late-stage asset. The HLP004 anxiety program is in Phase 2, and reports on 22 October 2026 place the next HLP004 study start in Q1 2027. A miss at week six would remove the lead program.
• Cash use is rising. Cash was $166.4 million at 30 June 2026, and operating cash used in the quarter was $37.1 million versus $29.5 million a year earlier (fiscal Q1 2027 release, 14 August 2026). The fiscal Q2 report, expected in mid-November, updates both figures.
• Management turnover before the data. Michael Cola left as chief executive in April 2026 and Michael Halstead took the role on 3 August 2026 (Simply Wall St management page). The co-founders stepped back from executive roles on 27 October 2026, weeks before the expected readout.
• Analyst targets sit far above the price. The TipRanks average target of $35.33 is more than three times the $10.52 close of 27 October 2026. The $22 Wells Fargo target is more than double it. The shares have not moved toward either level since mid-October.
• Gains since the offering are exposed. The 10.3-million-share offering priced at $4.85 on 24 June 2026, so a failed trial would return the shares toward or below that level.

Price setup

The last close was $10.52 on 27 October 2026. The 14-day relative strength index (RSI) is 50.1, neutral after readings of 28.1 on 14 October 2026 and above 70 on 10 September 2026 (Benzinga). The three-month price change is 29.2%, down from more than 100% in the 2 October 2026 note.

The 52-week high of $14.02 is 25.0% overhead. The $11.78 price level, the lower edge of the early-September range, stayed above the shares in the 14 October to 27 October 2026 window. A daily close below $9.00 would break the range the shares have held since mid-October.

Crowding evidence is limited to the topic's size. The company had 46.84M shares in its float out of 61.98M outstanding on 15 August 2026, and a float that size can gap in both directions on a binary result. The fiscal Q2 report, expected near 13 November 2026, and the topline, estimated near 15 November 2026 by TD Cowen, fall close together.

Catalysts, next 30 days

• ~13 November 2026, est.: fiscal Q2 2027 report (September quarter). Updates the $166.4M cash figure against $37.1M of quarterly operating cash use and may restate the APPROACH timeline.
• ~15 November 2026, est.: APPROACH Phase 3 topline for HLP003. TD Cowen's timing from 20 August 2026; the company guides only to Q4 2026 with no date. A six-week MADRS gain over placebo settles the case.
• 31 December 2026: end of the guided Q4 2026 topline window. This falls after the 30-day window but sets the point at which the timetable fails.

What would change the view

The case breaks if APPROACH misses its six-week primary endpoint, or if no topline is disclosed by 31 December 2026. A fiscal Q2 report showing operating cash use well above the $37.1 million of the June quarter, or a new equity offering ahead of the readout, would weaken it. A postponement of the Q4 2026 guidance at the November report would also count against it.

The price condition is a daily close below $9.00, which sits under the $10.52 close of 27 October 2026 and below the mid-October range.

What it trades with

HELP traded alongside ATAI and CMPS in two separate screens on 16 July 2026, so psychedelic-medicine sentiment moves the group together and single-name analysis understates that link. The shares also respond to small-cap biotech funding conditions, since the company has raised equity before its pivotal data. A Canadian line trades as HELP.NE beside the Nasdaq line, and the two can diverge intraday.